- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07335198
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry
En fase 1, randomiseret, placebokontrolleret, dobbeltblind, parallelgruppestudie til evaluering af sikkerhed, tolerabilitet, farmakokinetik og immunogenicitet af Efimosfermin Alfa administreret som en enkelt dosis til sunde deltagere af kinesisk, japansk og hvid/europæisk afstamning
This is a first time in Asia (FTIA) study designed to evaluate the safety, tolerability, pharmacokinetic (PK) and immunogenicity of efimosfermin alfa to healthy participants of Chinese, Japanese, and White/European ancestry.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
-
Auckland, New Zealand, 1010
- GSK Investigational Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Participants who are generally healthy as determined by medical evaluation
- Body weight at least 50.0 kilograms (kg) for male participants or at least 45.0 kg for female participants
- Body mass index (BMI) within the range of 18.0 to 28.0 kilograms per square meter (kg/m^2) (inclusive)
- Male and female participants
- Participants of Chinese ancestry are eligible if born in mainland China, Hong Kong, or Taiwan, and descendant of 2 ethnic Chinese parents and 4 ethnic Chinese grandparents; and have lived outside China, Hong Kong, or Taiwan for less than 10 years at the time of screening.
- Participants of Japanese ancestry are eligible if born in Japan and descendant of 2 ethnic Japanese parents and 4 ethnic Japanese grandparents; and have lived outside Japan for less than 10 years at the time of screening.
- Participants of White/European ancestry are eligible if self-identified as being of White/European ancestry, (that is [i.e.], from the original peoples of Europe) irrespective of current place of residence; and descendant of 2 parents and 4 grandparents of White/European ancestry (i.e., from the original peoples of Europe) irrespective of place of birth or current place of residence.
Exclusion Criteria:
- History or presence of disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
- Current or chronic history of liver or biliary disease with the exception of Gilbert's syndrome or asymptomatic gallstones.
- History of pancreatic injury, pancreatitis or other pancreatic disease; history of Type one Diabetes Mellitus (T1DM) or positive glutamic acid decarboxylase auto-antibodies, or major Type two Diabetes Mellitus (T2DM) complications including severe gastroparesis and autonomic neuropathy.
- Abnormal blood pressure (defined as systolic Blood Pressure [BP] more than equal [>=]140 millimeters of mercury [mmHg] or diastolic BP >=90 mmHg measured based on the average of triplicate BP readings).
- History of metabolic bone disorders including osteoporosis, osteopenia, or osteomalacia.
- History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years.
- Alanine transaminase (ALT) more than (>)1.5 * upper limit of normal (ULN).
- Total bilirubin >1.5 * ULN
- Known bleeding disorder.
- History of immunodeficiency diseases, including a positive test result for human immunodeficiency virus (HIV).
- Corrected QT Interval using Fridericia's Formula (QTcF) >=450 millisecond (msec)(male) or >=470 msec (female) at Screening Visit based on the average of triplicate ECGs.
- Use of statins, other lipid lowering medications or hypertension medications unless on a stable dose for at least 3 months.
- Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days, whichever was longer; or longer if required by local regulations.
- Participants who have received native FGF21 or a FGF21 analog at any time in the past.
- Intended use of over the counter (OTC) or prescription medication (including herbal medications) within 7 days prior to dosing and for the duration of study participation.
- Live vaccine within 14 days prior to dosing and non-live vaccines for 7 days prior study dosing.
- Current enrolment or participation in another clinical trial within the last 30 days before signing consent of current study.
- Presence of hepatitis B surface antigen (HBsAg) or hepatitis C antibody at screening or within 3 months prior to the first dose of study intervention
- A positive pre-study drug/alcohol screen
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Efimosfermin alfa in participants of Chinese Ancestry
Healthy participants of Chinese ancestry will be randomized to receive efimosfermin alfa. |
Efimosfermin alfa to be administered |
|
Eksperimentel: Efimosfermin alfa in participants of Japanese Ancestry
Healthy participants of Japanese ancestry will be randomized to receive efimosfermin alfa. |
Efimosfermin alfa to be administered |
|
Eksperimentel: Efimosfermin alfa in participants of White/European Ancestry
Healthy participants of White/European ancestry will be randomized to receive efimosfermin alfa. |
Efimosfermin alfa to be administered |
|
Placebo komparator: Placebo in participants of Chinese Ancestry
Healthy participants of Chinese ancestry will be randomized to receive Placebo. |
Placebo to be administered |
|
Placebo komparator: Placebo in participants of Japanese Ancestry
Healthy participants of Japanese ancestry will be randomized to receive Placebo. |
Placebo to be administered |
|
Placebo komparator: Placebo in participants of White/European Ancestry
Healthy participants of White/European ancestry will be randomized to receive Placebo. |
Placebo to be administered |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Antal deltagere med bivirkninger (AEs), behandlingsrelaterede bivirkninger og alvorlige bivirkninger (SAEs)
Tidsramme: Op til 90 dage
|
Op til 90 dage
|
|
Antal deltagere med klinisk signifikante ændringer i hematologi-, kemi- og urinanalysemål
Tidsramme: Op til 90 dage
|
Op til 90 dage
|
|
Antal deltagere med klinisk signifikante ændringer i 12-leds elektrokardiogram (EKG)
Tidsramme: Op til 90 dage
|
Op til 90 dage
|
|
Antal deltagere med klinisk signifikante ændringer i vitale tegn
Tidsramme: Op til 90 dage
|
Op til 90 dage
|
|
Arealet under serummedikamentkoncentrationskurven i forhold til tiden fra tid nul til tidspunktet for den sidste kvantificerbare koncentration (AUC[0-t]) af efimosfermin alfa
Tidsramme: Op til 90 dage
|
Op til 90 dage
|
|
Arealet under serum-lægemiddelkoncentration versus tidskurve fra tid nul ekstrapoleret til uendelig (AUC[0-inf]) af efimosfermin alfa
Tidsramme: Op til 90 dage
|
Op til 90 dage
|
|
Maksimal observeret serumkoncentration af lægemidlet, bestemt direkte fra serumkoncentration-tid-data (Cmax) for efimosfermin alfa
Tidsramme: Op til 90 dage
|
Op til 90 dage
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Tid til maksimal observeret serumkoncentration af efimosfermin alfa (Tmax)
Tidsramme: Op til 90 dage
|
Op til 90 dage
|
|
Tilsyneladende terminalfase halveringstid (t1/2) for efimosfermin alfa
Tidsramme: Op til 90 dage
|
Op til 90 dage
|
|
Areal under serumkoncentrationen af lægemidlet kontra tidskurven fra tid nul til 90 dage [AUC(0-90 dage)] for efimosfermin alfa
Tidsramme: Op til 90 dage
|
Op til 90 dage
|
|
Tidspunkt for sidste kvantificerbare plasmakoncentration (Tlast) af efimosfermin alfa
Tidsramme: Op til 90 dage
|
Op til 90 dage
|
|
Tilsyneladende clearance (CL/F) af efimosfermin alfa
Tidsramme: Op til 90 dage
|
Op til 90 dage
|
|
Tilsyneladende distributionsvolumen (Vz/F) for efimosfermin alfa
Tidsramme: Op til 90 dage
|
Op til 90 dage
|
|
Area under the serum drug concentration versus time curve from time zero to 45 days [AUC(0-45days)] of efimosfermin alfa
Tidsramme: Up to 45 days
|
Up to 45 days
|
|
Area under the serum drug concentration versus time curve from time zero to 60 days [AUC(0-60days)] of efimosfermin alfa
Tidsramme: Up to 60 days
|
Up to 60 days
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: GSK Clinical Trials, GlaxoSmithKline
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 301158
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
IPD-delingstidsramme
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
IPD-delingsadgangskriterier
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .